CCM
SRPT icon

Cinctive Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Cinctive Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-29,129
Closed -$4.6M – 508
2024
Q2 		$4.6M Sell
29,129
-49,231
-63% -$6.32M 0.22% 158
2024
Q1 		$10.1M Buy
+78,360
New +$9.6M 0.47% 63
2022
Q1 		– Sell
-13,300
Closed -$1.2M – 650
2021
Q4 		$1.2M Buy
+13,300
New +$1.14M 0.05% 380

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cinctive Capital Management's SRPT Position: Q3 2024 in Review

Cinctive Capital Management sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 29,129 shares — an estimated $4.6M sold.

Cinctive Capital Management first reported a position in SRPT in Q4 2021 and held it in 3 quarters. The position peaked at $10.1M in Q1 2024. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • Cinctive Capital Management reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Cinctive Capital Management sold 29,129 Sarepta Therapeutics shares in Q3 2024, an estimated $4.6M.
  • Cinctive Capital Management first reported a position in Sarepta Therapeutics in Q4 2021 and held it in 3 quarters.
  • Cinctive Capital Management's Sarepta Therapeutics position peaked at $10.1M in Q1 2024.
  • 457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Cinctive Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.